Trial Profile

A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guadecitabine (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Astex Pharmaceuticals

22 Jan 2025 Protocol has been amended to include new arms , changed from 2 to 13.
24 Aug 2017 Additional group of patients with 10 day schedule was added as per protocol amendment.
24 Aug 2017 Results (n=107, data cut off June 13, 2016) of final analysis of phase II study published in the Lancet Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com